TSC1-mTOR signaling determines the differentiation of islet cells

Area of Science:

• Endocrinology
• Metabolic Research
• Cellular Signaling

Background:

• Tuberous sclerosis complex 1 (TSC1) is a tumor suppressor gene.
• Mechanistic target of rapamycin complex 1 (mTORC1) signaling regulates cell growth and metabolism.
• The role of TSC1-mTORC1 signaling in pancreatic islet development and glucose homeostasis is not fully understood.

Purpose of the Study:

• To investigate the impact of TSC1 deletion in pancreatic islet cells on mTORC1 activation.
• To determine the effects of TSC1-mediated mTORC1 signaling on islet cell development and glucose metabolism.
• To explore the therapeutic potential of targeting TSC1-mTORC1 signaling in metabolic disorders.

Main Methods:

• Generated Neurogenin3-driven Tsc1 knockout mice (Neurogenin3-Tsc1-/-).
• Assessed mTORC1 activation via mTOR and S6 phosphorylation.
• Measured islet size, cell area, and hormone (insulin, glucagon, somatostatin) levels.
• Evaluated glucose tolerance and insulin sensitivity under standard and high-fat diet conditions.
• Administered rapamycin to assess its effects on mTORC1 signaling and glucose metabolism.

Main Results:

• Neurogenin3-Tsc1-/- mice exhibited elevated mTORC1 signaling, increased islet size, and enhanced insulin and somatostatin levels.
• Improved glucose tolerance was observed in Neurogenin3-Tsc1-/- mice on a standard diet, but impaired in those on a high-fat diet.
• Rapamycin treatment reversed mTORC1 activation, reduced beta-cell hypertrophy, and abolished the glucose tolerance improvement.

Conclusions:

• TSC1-mTORC1 signaling is crucial for pancreatic endocrine cell development.
• This signaling pathway plays a significant role in regulating glucose metabolism.
• Modulating TSC1-mTORC1 signaling may offer therapeutic strategies for metabolic diseases.